Zyprexa Zydis (Olanzapine) Patent Expiration, LOE Window & CMS Spending

Zyprexa Zydis (Olanzapine) by Cheplapharm Registration Gmbh: Off-Patent Genericized (AB Competition), 12 AB generics, $4.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCheplapharm Registration Gmbh
FDA Application & PathwayN021086 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$4.3M
2024 Medicare Part D Spend$3.0M
2024 Medicaid Spend$1.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel